Aytu BioPharma, Inc.
AYTUNASDAQHealthcare● Active
$2.29
+$0.04(+1.78%)
Market Cap$18547399
P/E Ratio—
52W High$3.07
52W Low$1.65
Aytu BioPharma, Inc. (AYTU) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AYTU · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.53
Est. -$0.31 · -71.0%
Revenue
$0.01B
Est. $0.01B · +3.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
AYTU reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$78.12
Rev. $1025.0B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$78.12
Rev. Est.$1025.0B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 29, 2026 | -$0.28 | — | — | — | $0.01B | — |
| ◌ Q3 FY2026 | Sep 22, 2026 | -$0.18 | — | — | — | $0.02B | — |
| ▼ Q2 FY2026 | May 13, 2026 | -$0.31 | -$0.53 | -71.0% | $0.01B | $0.01B | +3.0% |
| ▼ Q1 FY2026 | Feb 3, 2026 | -$0.26 | -$1.05 | -303.9% | $0.02B | $0.01B | +24.9% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.06 | -$0.08 | -33.3% | $0.01B | $0.01B | +10.2% |
| ▼ Q3 FY2025 | Sep 23, 2025 | -$0.02 | -$0.26 | -1200.0% | $0.02B | $0.02B | -15.6% |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.17 | $0.20 | +217.7% | $0.02B | $0.02B | -2.0% |
| — Q1 FY2025 | Feb 12, 2025 | -$0.28 | -$0.28 | +0.0% | $0.02B | $0.02B | -7.8% |
Q3 FY2026
Sep 29, 2026
EPS Actual
—
EPS Est.
-$0.28
EPS Surpr.
—
Revenue
—
Q3 FY2026
Sep 22, 2026
EPS Actual
—
EPS Est.
-$0.18
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Miss
EPS Actual
-$0.53
EPS Est.
-$0.31
EPS Surpr.
-71.0%
Revenue
$0.01B
Q1 FY2026
Feb 3, 2026Miss
EPS Actual
-$1.05
EPS Est.
-$0.26
EPS Surpr.
-303.9%
Revenue
$0.02B
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.08
EPS Est.
-$0.06
EPS Surpr.
-33.3%
Revenue
$0.01B
Q3 FY2025
Sep 23, 2025Miss
EPS Actual
-$0.26
EPS Est.
-$0.02
EPS Surpr.
-1200.0%
Revenue
$0.02B
Q2 FY2025
May 14, 2025Beat
EPS Actual
$0.20
EPS Est.
-$0.17
EPS Surpr.
+217.7%
Revenue
$0.02B
Q1 FY2025
Feb 12, 2025
EPS Actual
-$0.28
EPS Est.
-$0.28
EPS Surpr.
+0.0%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $0.17 | $0.17 | $0.17 | 1 |
| Q1 FY2027 | $0.10 | $0.10 | $0.10 | 1 |
| Q4 FY2026 | $0.03 | $0.03 | $0.03 | 1 |
| Q3 FY2026 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q2 FY2026 | $-0.28 | $-0.28 | $-0.27 | 1 |
| Q1 FY2026 | $-0.46 | $-0.44 | $-0.44 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -71.0% | $2.30 | $2.25 | -2.17% |
| ▼ Q1 FY2026 | Feb 3, 2026 | -303.9% | $2.71 | $2.62 | -3.32% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -33.3% | $2.06 | $2.06 | +0.00% |
| ▼ Q3 FY2025 | Sep 23, 2025 | -1200.0% | $2.49 | $2.51 | +0.80% |
| ▲ Q2 FY2025 | May 14, 2025 | +217.7% | $1.31 | $1.35 | +3.05% |
| ▲ Q1 FY2025 | Feb 12, 2025 | +0.0% | $1.42 | $1.39 | -2.11% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +41.2% | $1.74 | $1.75 | +0.57% |
| ▼ Q3 FY2024 | Sep 26, 2024 | -82.2% | $2.43 | $2.85 | +17.28% |
Q2 FY2026-2.17%
Report Date
May 13, 2026
EPS Beat/Miss
-71.0%
Price Before
$2.30
Price After
$2.25
Q1 FY2026-3.32%
Report Date
Feb 3, 2026
EPS Beat/Miss
-303.9%
Price Before
$2.71
Price After
$2.62
Q4 FY2025+0.00%
Report Date
Nov 13, 2025
EPS Beat/Miss
-33.3%
Price Before
$2.06
Price After
$2.06
Q3 FY2025+0.80%
Report Date
Sep 23, 2025
EPS Beat/Miss
-1200.0%
Price Before
$2.49
Price After
$2.51
Q2 FY2025+3.05%
Report Date
May 14, 2025
EPS Beat/Miss
+217.7%
Price Before
$1.31
Price After
$1.35
Q1 FY2025-2.11%
Report Date
Feb 12, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.42
Price After
$1.39
Q4 FY2024+0.57%
Report Date
Nov 13, 2024
EPS Beat/Miss
+41.2%
Price Before
$1.74
Price After
$1.75
Q3 FY2024+17.28%
Report Date
Sep 26, 2024
EPS Beat/Miss
-82.2%
Price Before
$2.43
Price After
$2.85
Avg Beat Reaction+0.50%
Avg Miss Reaction+2.52%
Beat Rate3 / 8 quarters
Largest Move+17.28% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AYTU ends December
Aytu BioPharma, Inc. (AYTU) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.53 — missing the analyst consensus of $-0.31 by -71.0%. The next AYTU earnings date is expected around September 1, 2026.
Each quarter, investors track AYTU earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AYTU revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AYTU's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AYTU earnings · 5 questionsAytu BioPharma, Inc.'s next earnings report is expected around September 1, 2026. AYTU typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AYTU historically reports after market close (AMC).
AYTU earnings datewhen is AYTU earningsAYTU next earnings datewhen does AYTU report earningsAYTU earnings calendar
▸ Source: FMP · Aytu BioPharma, Inc. SEC filings · US GAAP · Aytu BioPharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026